Dextrothyroxine

Dextrothyroxine
Systematic (IUPAC) name
(2R)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid
Clinical data
Trade names Choloxin
AHFS/Drugs.com Multum Consumer Information
  • US: B (No risk in non-human studies)
  • Discontinued
Identifiers
51-49-0
C10AX01
PubChem CID 8730
DrugBank DB00509
ChemSpider 8402
UNII 4W9K63FION
ChEBI CHEBI:30659
ChEMBL CHEMBL559
Synonyms D-3,5,3',5'-tetraiodothyronine
Chemical data
Formula C15H11I4NO4
776.87 g/mol

Dextrothyroxine (trade name Choloxin) saw research as an cholesterol-lowering drug[1][2] but was pulled due to cardiac side-effects. It also increases hepatic lipase which in turn improves utilization of triglycerides, improving apolipoprotein E cholesterol particles.

See also

References

  1. ↑ Bantle, J. P.; Hunninghake, D. B.; Frantz, I. D.; Kuba, K.; Mariash, C. N.; Oppenheimer, J. H. (1984). "Comparison of effectiveness of thyrotropin-suppressive doses of D- and L-thyroxine in treatment of hypercholesterolemia". The American journal of medicine 77 (3): 475–481. doi:10.1016/0002-9343(84)90107-4. PMID 6475988.
  2. ↑ Bommer, C.; Werle, E.; Walter-Sack, I.; Keller, C.; Gehlen, F.; Wanner, C.; Nauck, M.; März, W.; Wieland, H.; Bommer, J. (1998). "D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients". Journal of the American Society of Nephrology : JASN 9 (1): 90–96. PMID 9440092.